m+Medelevator.RU
← Поиск публикаций
Stem cell reports · 2026

Donor-intrinsic regenerative potential outweighs histocompatibility in iPSC-derived skeletal muscle engraftment in nonhuman primates.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Rashid Muhammad Irfanur, Kiley James, Azzag Karim, Crist Sarah B, Murphy Ethan, Lihnakevic Joshua, Stone Laura Hocum, Janecek Jody L, Rangarajan Parthasarathy, Yamashita Aline M S, Dhoke Neha, Jain Arreh, Ramachandran Sabarinathan, Graham Melanie L, Perlingeiro Rita C R

Аннотация

Cell-based regenerative therapies represent a promising platform for muscular dystrophies, but the role of histocompatibility for muscle engraftment remains poorly defined. Given their close genetic relationship to humans, nonhuman primate (NHP) models provide an ideal system to investigate this question. Here, we generated myogenic progenitors from induced pluripotent stem cell (iPSC) lines derived from five major histocompatibility complex (MHC)-typed Mauritian-origin cynomolgus macaques (MCMs). Following extensive characterization, one iPSC clone from each donor was selected for transplantation across distinct MHC matching conditions, including fully matched, partially matched, and mismatched recipient-donor pairs. We found that variation in regenerative potential was primarily donor-intrinsic. Strikingly, fully mismatched donor-derived myogenic progenitors exhibiting high regenerative potential consistently outperformed partially and fully matched grafts across recipients. Our results suggest that, under clinically relevant immunosuppression, donor-intrinsic regenerative potential may outweigh histocompatibility as a determinant of early skeletal muscle engraftment, supporting the development of broadly applicable off-the-shelf allogeneic iPSC-based therapies for muscular dystrophies.